Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2026
상품코드:1957756
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
리보핵산(RNA) 기반 종양 용해 요법 시장 규모는 최근 급성장하고 있습니다. 2025년 21억 2,000만 달러에서 2026년에는 25억 1,000만 달러에 이르고, CAGR 18.7%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 암 바이러스학 연구의 발전, 종양 면역학에 대한 이해의 심화, 임상시험 인프라의 정비, 종양학 연구 자금 증가, 종양 용해성 바이러스 연구의 초기 단계의 성공에 기인한다고 볼 수 있습니다.
리보핵산(RNA) 기반 종양용해성 요법 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 49억 4,000만 달러에 이르고, CAGR은 18.4%를 나타낼 전망입니다. 예측 기간 동안의 성장은 RNA 기반 암 치료제 승인 증가, 맞춤형 암 치료 수요 증가, 면역항암제 파이프라인 확대, 유전자 및 세포치료제 투자 증가, RNA 전달 시스템 기술 발전 등에 기인할 것으로 예측됩니다. 예측 기간의 주요 동향으로는 RNA 바이러스 공학의 발전, 복합 종양 용해 요법의 도입 증가, 면역 체계 활성화에 대한 관심 증가, 표적 종양 특이적 RNA 치료의 확대, 정밀 종양학 도구의 통합 강화 등을 꼽을 수 있습니다.
개인 맞춤형 의료의 도입 확대는 향후 몇 년 동안 RNA 기반 종양 용해성 치료제 시장의 성장을 견인할 것으로 예측됩니다. 개인 맞춤형 의료란 개인의 유전자 프로파일을 기반으로 설계된 치료법을 말하며, 효능은 높이고 부작용은 최소화하는 치료법을 말합니다. 더 많은 의료 서비스 제공업체와 기관이 표적 치료와 정밀 진단을 통해 환자 결과를 개선할 수 있는 가능성을 인식함에 따라 개인 맞춤형 의료의 활용이 증가하고 있습니다. RNA 기반 종양 용해 요법은 표적화된 환자별 치료 전략을 제공함으로써 개인 맞춤형 의료의 도입을 지원하며, 암 치료에 있어 매우 중요한 역할을 합니다. 예를 들어, 2024년 2월 미국 맞춤형 의료 추진 단체인 'Personalized Medicine Coalition'은 2023년 FDA가 희귀질환 환자를 위한 16건의 새로운 개인맞춤형 치료제를 승인했다고 보고했다(2022년 6건). 이처럼 개인 맞춤형 의료의 보급 확대가 RNA 기반 종양 용해 치료제 시장을 견인하고 있습니다.
주요 기업들은 종양 표적 효율 향상, 면역 반응 강화, 보다 정밀하고 지속적인 암 치료 성과 달성을 위한 합성 메신저 RNA(mRNA) 기술 등 혁신 기술 개발에 집중하며 리보핵산(RNA) 기반 종양 용해 치료제 시장에서 활발히 활동하고 있습니다. 합성 메신저 RNA(mRNA) 기술은 실험실에서 설계된 mRNA 서열을 만들어 전달하고, 암을 포함한 질병 관리를 위한 특정 치료용 단백질을 세포에서 생산하도록 지시하는 생명공학 기술입니다. 예를 들어, 2024년 6월 중국계 제약기업인 CSPC Pharmaceutical Group Limited는 합성 mRNA 기반 암세포 치료제 'SYS6020'에 대한 중국 내 임상시험 시작에 대한 규제 당국의 승인을 받았습니다. 이 획기적인 발전은 국내 메신저 RNA 치료 분야에서 중요한 진전을 이룬 것으로 평가받고 있습니다. SYS6020은 mRNA-지질 나노입자 기술을 이용하여 부작용을 최소화하면서 골수종 암세포를 선택적으로 표적화하여 파괴하며, 특정 자가면역질환의 치료 가능성도 시사하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that employs engineered RNA viruses to specifically target and destroy tumor cells. These viruses multiply within cancer cells, leading to their elimination and the release of tumor antigens. This process also activates the immune system to identify and attack any remaining cancer cells, improving overall anti-tumor effectiveness.
The primary therapy types of ribonucleic acid (RNA)-based oncolytic therapy include messenger ribonucleic acid (mRNA)-based oncolytic therapy, small interfering ribonucleic acid (siRNA)-based oncolytic therapy, micro ribonucleic acid (miRNA)-based oncolytic therapy, and other therapy types. Messenger ribonucleic acid (mRNA)-based oncolytic therapy involves the use of synthetic mRNA molecules designed to stimulate the immune system or directly trigger tumor cell death, providing a targeted and flexible approach to cancer treatment. These therapies are delivered via routes such as intravenous, intratumoral, and other methods, and are used in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The main end-users include hospitals, cancer research institutes, specialty clinics, and others.
Tariffs are influencing the RNA-based oncolytic therapy market by increasing costs of imported nucleic acids, viral vectors, lipid nanoparticles, bioprocessing equipment, and cold-chain logistics systems. Cancer research institutes and hospitals in North America and Europe are most affected due to reliance on imported high-purity RNA materials, while Asia-Pacific faces higher costs in advanced therapy manufacturing. These tariffs are increasing development and trial costs and extending commercialization timelines. At the same time, they are encouraging domestic biomanufacturing, regional sourcing of RNA components, and investment in local advanced therapy production capabilities.
The ribonucleic acid (rna)-based oncolytic therapy market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna)-based oncolytic therapy market statistics, including ribonucleic acid (rna)-based oncolytic therapy industry global market size, regional shares, competitors with a ribonucleic acid (rna)-based oncolytic therapy market share, detailed ribonucleic acid (rna)-based oncolytic therapy market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna)-based oncolytic therapy industry. This ribonucleic acid (rna)-based oncolytic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ribonucleic acid (rna)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $2.12 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 18.7%. The growth in the historic period can be attributed to advancements in cancer virology research, increasing understanding of tumor immunology, availability of clinical trial infrastructure, rising oncology research funding, early success of oncolytic virus studies.
The ribonucleic acid (rna)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.94 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing approvals of rna-based cancer therapies, rising demand for personalized oncology treatments, expansion of immuno-oncology pipelines, growing investment in gene and cell therapies, technological advancements in rna delivery systems. Major trends in the forecast period include increasing advancement of rna virus engineering, rising adoption of combination oncolytic therapies, growing focus on immune system activation, expansion of targeted tumor-specific rna therapies, enhanced integration of precision oncology tools.
The increasing adoption of personalized medicine is anticipated to drive the growth of the RNA-based oncolytic therapy market in the coming years. Personalized medicine refers to treatments designed according to an individual's genetic profile, enhancing effectiveness and minimizing side effects. The use of personalized medicine is rising as more healthcare providers and institutions acknowledge its potential to improve patient outcomes through targeted therapies and precision diagnostics. RNA-based oncolytic therapy is pivotal in cancer care, supporting the adoption of personalized medicine by providing targeted, patient-specific treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy organization for tailored medical treatments, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared to 6 in 2022. Thus, the expanding adoption of personalized medicine is propelling the RNA-based oncolytic therapy market.
Major companies are active in the ribonucleic acid (RNA)-based oncolytic therapy market, concentrating on developing technological innovations such as synthetic messenger RNA (mRNA) technology to improve tumor-targeting efficiency, enhance immune response, and achieve more precise and long-lasting cancer treatment outcomes. Synthetic messenger RNA (mRNA) technology is a biotechnology method that creates and delivers lab-designed mRNA sequences to instruct cells to produce specific therapeutic proteins for disease management, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a China-based pharmaceutical company, obtained regulatory approval in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This milestone marks a significant advancement in the nation's messenger RNA therapeutics field. SYS6020 uses mRNA-lipid nanoparticle technology to selectively target and destroy myeloma cancer cells with minimal side effects, while also showing potential for treating certain autoimmune disorders.
In June 2023, Charles River Laboratories International, Inc., a US-based contract research organization (CRO), teamed up with Curigin Co., Ltd. to develop oncolytic RNAi gene therapy. Through this partnership, the goal is to accelerate the development and production of Curigin's RNAi-based oncolytic gene therapies by drawing on Charles River's CDMO expertise to aid preclinical and clinical trials. Curigin Co. Ltd. is a South Korea-based biotechnology company focused on creating RNA interference (RNAi)-based oncolytic gene therapies for cancer treatment.
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses ribonucleic acid (rna)-based oncolytic therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ribonucleic acid (rna)-based oncolytic therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna)-based oncolytic therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy; Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy; Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy; Other Therapy Types
2) By Route Of Administration: Intravenous; Intratumoral; Other Route Of Administrations
3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Other Applications
4) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Other End-Users
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Industry 4.0 & Intelligent Manufacturing
4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increasing Advancement Of RNA Virus Engineering
4.2.2 Rising Adoption Of Combination Oncolytic Therapies
4.2.3 Growing Focus On Immune System Activation
4.2.4 Expansion Of Targeted Tumor-Specific RNA Therapies
4.2.5 Enhanced Integration Of Precision Oncology Tools
5. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Cancer Research Institutes
5.3 Specialty Oncology Clinics
5.4 Academic Research Centers
5.5 Biopharmaceutical Companies
6. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
9.8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
10. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional And Country Analysis
10.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
12.1. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
13.1. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
14.1. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
15.1. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
16.1. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
17.1. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
19.1. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
20.1. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
21.1. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
23.1. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
26.1. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
27.1. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
28.1. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
29.1. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
31.1. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
32.1. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
33.1. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
34.1. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
